Perceptic, a startup building an AI operating system for biopharma, has emerged from stealth with a $12 million seed round led by Air Street Capital and Accel, with participation from angel investors.
The company says its software connects research, development and clinical decision-making across the full lifecycle of a drug. Its platform includes products such as Scout, PercepticOS and Atlas, designed to link data, decisions and context across drug development workflows.
Perceptic is entering the market with early traction. The company says its technology is already being used by multiple top-20 pharmaceutical companies, including CSL.
The funding highlights continued investor interest in AI infrastructure for life sciences, particularly tools aimed at improving how drugmakers work across fragmented R&D and clinical systems.
The company says its software connects research, development and clinical decision-making across the full lifecycle of a drug. Its platform includes products such as Scout, PercepticOS and Atlas, designed to link data, decisions and context across drug development workflows.
Perceptic is entering the market with early traction. The company says its technology is already being used by multiple top-20 pharmaceutical companies, including CSL.
The funding highlights continued investor interest in AI infrastructure for life sciences, particularly tools aimed at improving how drugmakers work across fragmented R&D and clinical systems.